tiprankstipranks
Henry Schein (CH:HS2)
:HS2
Switzerland Market
HS2
Henry Schein
RESEARCH TOOLSreports

Henry Schein (HS2) Stock Forecast & Price Target

0 Followers
See the Price Targets and Ratings of:

HS2 Analyst Ratings

Moderate Buy
13Ratings
Moderate Buy
7 Buy
5 Hold
1 Sell
Based on 13 analysts giving stock ratings to
Henry
Schein
in the past 3 months
TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers​ in the past 3 months

HS2 Stock 12 Month Forecast

Average Price Target

CHF69.03
Based on 13 Wall Street analysts offering 12 month price targets for Henry Schein in the last 3 months. The average price target is CHF69.03 with a high forecast of CHF79.93 and a low forecast of CHF51.15. The average price target represents a ― change from the last price of ―.
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
Highest Price TargetCHF79.93Average Price TargetCHF69.03Lowest Price TargetCHF51.15
The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts​

Detailed List of Analyst Forecasts​
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on CH:HS2
Jason Bednar
Piper Sandler
Piper Sandler
CHF79.13→CHF72.73
Buy
―
Reiterated
06/10/26
Analysts Are Bullish on Top Healthcare Stocks: Centene (CNC), Henry Schein (HSIC)
Bank of America Securities Analyst forecast on CH:HS2
Allen Lutz
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: Henry Schein (NASDAQ: HSIC), Insulet (NASDAQ: PODD) and Gilead Sciences (NASDAQ: GILD)
Barclays Analyst forecast on CH:HS2
Glen Santangelo
Barclays
Barclays
CHF68.74
Buy
―
Assigned
05/07/26
Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (NASDAQ: LMAT), Henry Schein (NASDAQ: HSIC) and Exelixis (NASDAQ: EXEL)
Robert W. Baird Analyst forecast on CH:HS2
Jeff Johnson
Robert W. Baird
Robert W. Baird
CHF83.12→CHF77.53
Buy
―
Reiterated
05/06/26
Henry Schein price target lowered to $97 from $104 at BairdHenry Schein price target lowered to $97 from $104 at Baird
Stifel Nicolaus Analyst forecast on CH:HS2
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
CHF67.14
Hold
―
Reiterated
05/06/26
Stifel Nicolaus Keeps Their Hold Rating on Henry Schein (HSIC)
UBS Analyst forecast on CH:HS2
Kevin Caliendo
UBS
UBS
CHF69.54→CHF67.94
Hold
―
Reiterated
05/06/26
Henry Schein price target lowered to $85 from $87 at UBSHenry Schein price target lowered to $85 from $87 at UBS
Barrington Analyst forecast on CH:HS2
Michael Petusky
Barrington
Barrington
CHF77.53
Buy
―
Reiterated
05/06/26
Analysts Are Bullish on Top Healthcare Stocks: Henry Schein (HSIC), Alphatec Holdings (ATEC)
Mizuho Securities Analyst forecast on CH:HS2
Steven Valiquette
Mizuho Securities
Mizuho Securities
CHF70.34→CHF65.54
Hold
―
Reiterated
05/06/26
Henry Schein price target lowered to $82 from $88 at MizuhoHenry Schein price target lowered to $82 from $88 at Mizuho
Morgan Stanley Analyst forecast on CH:HS2
Erin Wright
Morgan Stanley
Morgan Stanley
CHF48.76→CHF51.15
Sell
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (NASDAQ: RYTM), Henry Schein (NASDAQ: HSIC) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Evercore ISI Analyst forecast on CH:HS2
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
CHF71.93
Buy
―
Reiterated
05/05/26
Evercore ISI Remains a Buy on Henry Schein (HSIC)
William Blair Analyst forecast on CH:HS2
Brandon Vazquez
William Blair
William Blair
CHF59.15
Hold
―
Reiterated
05/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Henry Schein (NASDAQ: HSIC), Viridian Therapeutics (NASDAQ: VRDN) and Q32 Bio (NASDAQ: QTTB)
BTIG Analyst forecast on CH:HS2
David Larsen
BTIG
BTIG
―
Hold
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (NASDAQ: QDEL), Climb Bio (NASDAQ: CLYM) and Henry Schein (NASDAQ: HSIC)
Citi Analyst forecast on CH:HS2
Daniel Grosslight
Citi
Citi
CHF79.93
Buy
―
Initiated
04/16/26
Henry Schein initiated with a Buy at CitiHenry Schein initiated with a Buy at Citi
Wells Fargo Analyst forecast on CH:HS2
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
CHF60.74→CHF69.54
Hold
―
Reiterated
02/25/26
Wells Fargo Reaffirms Their Hold Rating on Henry Schein (HSIC)
J.P. Morgan Analyst forecast on CH:HS2
John Stansel
J.P. Morgan
J.P. Morgan
CHF62.34→CHF73.53
Buy
―
Reiterated
02/25/26
Henry Schein price target raised to $92 from $78 at JPMorganHenry Schein price target raised to $92 from $78 at JPMorgan
Analyst Type
Any
Any
Human Analysts
Ranks
Any
Any
Analyst Rating
Any
Any
Upside/ Downside
Any
Any
Action
Any
Any
Analyst Profile
Expert Firm
Price Target
Position
Upside / Downside
Action
Date
Follow
Article
Piper Sandler Analyst forecast on CH:HS2
Jason Bednar
Piper Sandler
Piper Sandler
CHF79.13→CHF72.73
Buy
―
Reiterated
06/10/26
Analysts Are Bullish on Top Healthcare Stocks: Centene (CNC), Henry Schein (HSIC)
Bank of America Securities Analyst forecast on CH:HS2
Allen Lutz
Bank of America Securities
Bank of America Securities
―
Buy
―
Reiterated
05/14/26
Analysts Offer Insights on Healthcare Companies: Henry Schein (NASDAQ: HSIC), Insulet (NASDAQ: PODD) and Gilead Sciences (NASDAQ: GILD)
Barclays Analyst forecast on CH:HS2
Glen Santangelo
Barclays
Barclays
CHF68.74
Buy
―
Assigned
05/07/26
Analysts Offer Insights on Healthcare Companies: Lemaitre Vascular (NASDAQ: LMAT), Henry Schein (NASDAQ: HSIC) and Exelixis (NASDAQ: EXEL)
Robert W. Baird Analyst forecast on CH:HS2
Jeff Johnson
Robert W. Baird
Robert W. Baird
CHF83.12→CHF77.53
Buy
―
Reiterated
05/06/26
Henry Schein price target lowered to $97 from $104 at BairdHenry Schein price target lowered to $97 from $104 at Baird
Stifel Nicolaus Analyst forecast on CH:HS2
Jonathan Block
Stifel Nicolaus
Stifel Nicolaus
CHF67.14
Hold
―
Reiterated
05/06/26
Stifel Nicolaus Keeps Their Hold Rating on Henry Schein (HSIC)
UBS Analyst forecast on CH:HS2
Kevin Caliendo
UBS
UBS
CHF69.54→CHF67.94
Hold
―
Reiterated
05/06/26
Henry Schein price target lowered to $85 from $87 at UBSHenry Schein price target lowered to $85 from $87 at UBS
Barrington Analyst forecast on CH:HS2
Michael Petusky
Barrington
Barrington
CHF77.53
Buy
―
Reiterated
05/06/26
Analysts Are Bullish on Top Healthcare Stocks: Henry Schein (HSIC), Alphatec Holdings (ATEC)
Mizuho Securities Analyst forecast on CH:HS2
Steven Valiquette
Mizuho Securities
Mizuho Securities
CHF70.34→CHF65.54
Hold
―
Reiterated
05/06/26
Henry Schein price target lowered to $82 from $88 at MizuhoHenry Schein price target lowered to $82 from $88 at Mizuho
Morgan Stanley Analyst forecast on CH:HS2
Erin Wright
Morgan Stanley
Morgan Stanley
CHF48.76→CHF51.15
Sell
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: Rhythm Pharmaceuticals (NASDAQ: RYTM), Henry Schein (NASDAQ: HSIC) and Ultragenyx Pharmaceutical (NASDAQ: RARE)
Evercore ISI Analyst forecast on CH:HS2
Elizabeth Anderson CFA
Evercore ISI
Evercore ISI
CHF71.93
Buy
―
Reiterated
05/05/26
Evercore ISI Remains a Buy on Henry Schein (HSIC)
William Blair Analyst forecast on CH:HS2
Brandon Vazquez
William Blair
William Blair
CHF59.15
Hold
―
Reiterated
05/05/26
Analysts' Opinions Are Mixed on These Healthcare Stocks: Henry Schein (NASDAQ: HSIC), Viridian Therapeutics (NASDAQ: VRDN) and Q32 Bio (NASDAQ: QTTB)
BTIG Analyst forecast on CH:HS2
David Larsen
BTIG
BTIG
―
Hold
―
Reiterated
05/05/26
Analysts Offer Insights on Healthcare Companies: QuidelOrtho (NASDAQ: QDEL), Climb Bio (NASDAQ: CLYM) and Henry Schein (NASDAQ: HSIC)
Citi Analyst forecast on CH:HS2
Daniel Grosslight
Citi
Citi
CHF79.93
Buy
―
Initiated
04/16/26
Henry Schein initiated with a Buy at CitiHenry Schein initiated with a Buy at Citi
Wells Fargo Analyst forecast on CH:HS2
Unknown Analyst
Wells Fargo
Not Ranked
Wells Fargo
CHF60.74→CHF69.54
Hold
―
Reiterated
02/25/26
Wells Fargo Reaffirms Their Hold Rating on Henry Schein (HSIC)
J.P. Morgan Analyst forecast on CH:HS2
John Stansel
J.P. Morgan
J.P. Morgan
CHF62.34→CHF73.53
Buy
―
Reiterated
02/25/26
Henry Schein price target raised to $92 from $78 at JPMorganHenry Schein price target raised to $92 from $78 at JPMorgan
Stocks with the Highest Top Analyst Consensus in the Healthcare Sector
TRAXFirst Tracks Biotherapeutics Inc
EVMNEvommune, Inc.
MPLTMapLight Therapeutics, Inc.
MAZEMaze Therapeutics, Inc.
AAPGAscentage Pharma Group International Unsponsored ADR
Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Henry Schein

3 Months
Michael PetuskyBarrington
Success Rate
21/37 ratings generated profit
57%
Average Return
+2.26%
Copying Michael Petusky's trades and holding each position for 3 Months would result in 56.76% of your transactions generating a profit, with an average return of +2.26% per trade.
1 Year
Allen LutzBank of America Securities
Success Rate
11/16 ratings generated profit
69%
Average Return
+6.14%
Copying Allen Lutz's trades and holding each position for 1 Year would result in 68.75% of your transactions generating a profit, with an average return of +6.14% per trade.
2 Years
Allen LutzBank of America Securities
Success Rate
11/16 ratings generated profit
69%
Average Return
+7.09%
Copying Allen Lutz's trades and holding each position for 2 Years would result in 68.75% of your transactions generating a profit, with an average return of +7.09% per trade.
The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HS2 Analyst Recommendation Trends

Rating
Feb 26
Mar 26
Apr 26
May 26
Jun 26
Strong Buy
0
0
0
0
0
Buy
12
14
12
12
9
Hold
9
11
10
8
6
Sell
1
1
2
2
2
Strong Sell
0
0
0
0
0
total
22
26
24
22
17
In the current month, HS2 has received 9 Buy Ratings, 6 Hold Ratings, and 2 Sell Ratings. HS2 average Analyst price target in the past 3 months is 69.03.
Each month's total comprises the sum of three months' worth of ratings.

HS2 Financial Forecast

HS2 Earnings Forecast

Next quarter’s earnings estimate for HS2 is CHF0.99 with a range of CHF0.93 to CHF1.09. The previous quarter’s EPS was CHF1.05. HS2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year HS2 has Performed in-line its overall industry.
Next quarter’s earnings estimate for HS2 is CHF0.99 with a range of CHF0.93 to CHF1.09. The previous quarter’s EPS was CHF1.05. HS2 beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 56.87% of the time in the same period. In the last calendar year HS2 has Performed in-line its overall industry.

HS2 Sales Forecast

Next quarter’s sales forecast for HS2 is CHF2.70B with a range of CHF2.67B to CHF2.72B. The previous quarter’s sales results were CHF2.69B. HS2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year HS2 has Performed in-line its overall industry.
Next quarter’s sales forecast for HS2 is CHF2.70B with a range of CHF2.67B to CHF2.72B. The previous quarter’s sales results were CHF2.69B. HS2 beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 50.06% of the time in the same period. In the last calendar year HS2 has Performed in-line its overall industry.

HS2 Stock Forecast FAQ

What is CH:HS2’s average 12-month price target, according to analysts?
Based on analyst ratings, Henry Schein’s 12-month average price target is 69.03.
    What is CH:HS2’s upside potential, based on the analysts’ average price target?
    Currently there's no upside potential for CH:HS2, based on the analysts’ average price target.
    Can I see which stocks the top-ranking analysts are rating?
    Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.
      How can I follow the stock ratings of top Wall Street analysts?
      Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.
        Is Henry Schein a Buy, Sell or Hold?
        Henry Schein has a consensus rating of Moderate Buy, which is based on 7 buy ratings, 5 hold ratings and 1 sell ratings.
          What is Henry Schein’s share price target?
          The average share price target for Henry Schein is 69.03. This is based on 13 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
          The highest analyst share price target is CHF79.93 ,and the lowest forecast is CHF51.15. The average share price target represents N/A Increase from the current price of N/A.
            What do analysts say about Henry Schein?
            Henry Schein’s analyst rating consensus is a Moderate Buy. This is based on the ratings of 13 Wall Streets Analysts.
              How can I buy shares of Henry Schein?
              To buy shares of CH:HS2, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.